Downing

"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."

"There has been a major generational shift in consumer behaviour that has stemmed from a trust crisis – trust in institutions, in brands, and in advertising is at an all-time low."

"The current crisis has accelerated the trend towards digitisation and the use of intelligent decisioning that uses access to live data. We are delighted that our investors are seeing the significant opportunity to transform SME lending to make funding more accessible, more affordable and more sustainable through the deployment of our intelligent infrastructure."

"We are delighted to be bringing such high-profile investors on board, who share our ambitious growth plans for the business. This significant investment is a strong endorsement of the MIPs technology, it will enable us to scale our operations and take the business to the next level. MIPs offer many advantages and provide solutions to enable new applications that push the limit of what was previously possible. This investment will enable us to rapidly expand our operations to service these opportunities and bring exciting new products to the market."

"At Abaka, we believe that harnessing AI-led solutions has the potential to revolutionise the retirement and savings industry, using what we call Artificial Financial Intelligence to help financial services companies better engage their clients in financial planning."